Cambridge Healthtech Institute’s Inaugural
Emerging Cancer Targets for Multispecifics, ADCs, and Biologics
September 24th-25th, 2025
What new cancer targets are showing promise? Which new biologic modalities and strategies have led to recent breakthroughs with existing targets? Join us for the Inaugural Emerging Cancer Targets for Multispecifics, ADCs, and Biologics conference, where we address these questions by tackling persistent challenges and exploring recent advancements in oncology and autoimmunity. Key issues we will discuss include ligand solubility, sustaining target engagement, lack of tumor-specific ligand expression, risk of immune activation, understanding ligand-receptor dynamics, short ligand half-lives, the need for new targets, and narrow therapeutic applicability. Sessions examine these topics through the lens of targeting the tumor microenvironment (TME), immune checkpoint targeting, and cytokine and growth factor targeting.
Who should attend:
- Researchers interested in:
- Oncology
- Autoimmunity
- Immunology
- Bispecifics/multispecifics
- ADCs
- The tumor microenvironment (TME)
- Biologic drug development
- Target discovery
- Regulatory affairs
Coverage will include, but is not limited to:
- Targeting the TME
- Fibroblast Activation Protein (FAP)
- CXCL12/CXCR4
- GPC3 (Glypican-3)
- TSP1
- Emerging Immune Checkpoints
- Cytokines and Growth Factors
The deadline for priority consideration is March 7, 2025.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation: